Iradimed Co Stock Math Transform Inverse Tangent Over Price Movement
| IRMD Stock | USD 99.69 0.32 0.32% |
| Symbol |
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Iradimed Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Iradimed price patterns.
Iradimed Technical Analysis Modules
Most technical analysis of Iradimed help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Iradimed from various momentum indicators to cycle indicators. When you analyze Iradimed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging compatible medical devices, and related accessories and services in the United States and internationally. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida. Iradimed operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Market structure and macro sensitivity help explain how Iradimed behaves across regimes. Price movements may be comparatively less responsive to macroeconomic volatility. Iradimed has a market cap of 1.26 B, P/E of 28.7, ROE of 24.78%.
Methodology
Unless otherwise specified, financial data for Iradimed Co is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Iradimed (USA Stocks:IRMD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The data underlying this report is sourced from public filings and market reference sources, including filings and releases published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Some updates may be delayed based on publication cadence. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Iradimed Co may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Iradimed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Iradimed's short interest history, or implied volatility extrapolated from Iradimed options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Data Storage Invested few shares | |
 | Investor Favorites Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Blockchain Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Momentum Invested few shares | |
 | Cash Cows Invested few shares | |
 | Hedge Favorites Invested over 200 shares | |
 | Advertising Invested few shares | |
More Resources for Iradimed Stock Analysis
A comprehensive view of Iradimed starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for Iradimed Co Stock. Selected reports below provide context for Iradimed Stock:Iradimed has a market cap of 1.26 B, operating margin of 31.26%, ROE of 24.78%. Review Risk vs Return Analysis for broader portfolio context. This reflects a position in Iradimed Co within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Analysis related to Iradimed should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Quarterly Earnings Growth 0.248 | Dividend Share 0.71 | Earnings Share 1.75 | Revenue Per Share | Quarterly Revenue Growth 0.17 |
Understanding Iradimed includes distinguishing between market value and book value, where book value reflects Iradimed's accounting equity. Iradimed's market capitalization is 1.26 B. With a P/B ratio of 13.41, the market values Iradimed well above its book equity. Enterprise value stands at 1.22 B. Intrinsic value reflects what Iradimed's fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Iradimed's value from its trading price, which are computed with different methods. For Iradimed, key inputs include a P/E ratio of 28.7, a P/B ratio of 13.41, a profit margin of 26.82%, and ROE of 24.78%. The quoted price is simply the exchange level where supply meets demand.